You are here:

levetiracetam 250 500 750 and 1000mg tablets and levetircetam oral solution 100mg/ml (Keppra)

Advice

Following a resubmission

levetiracetam (Keppra®) is accepted for restricted use within NHS Scotland as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Levetiracetam has been shown to be non-inferior to an older first choice anti-epileptic drug for partial seizures.

Levetiracetam is significantly more expensive than traditional drugs so its use is restricted to patients for whom the range of traditional drugs normally used for first-line treatment are ineffective or unsuitable.

Drug Details

Drug Name: levetiracetam 250 500 750 and 1000mg tablets and levetircetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 397/07
Manufacturer: UCB Pharma Ltd
Indication: Monotherapy for epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 11 February 2008

Archived Advice

Full submission 10 September 2007

Back